VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Combination nicotine replacement therapy
Preclinical
Small molecule
S
State University of New York at Buffalo
1
Indications
3
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Smokeless Tobacco
Unknown status
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Smokeless Tobacco
Preclinical
Unknown status
Clinical
Trials by Indication
[1]
Tobacco
1 trial
UW Withdraw From Tobacco Study
Completed
·
U
University of Wisconsin, Madison
·
Phase 2
·
NCT04969198
·
232 enrolled
Smokeless Tobacco
1 trial
Treating Smokeless Tobacco Use in Rural Veterans
Unknown status
·
M
Mark Vander Weg
·
N/A
·
NCT02994082
·
123 enrolled
Remote vs. In-Person
1 trial
Improving Efficiency, Quality, and Equity: Randomized Controlled Evaluations of Remote vs. In-Person Clinical Trial Methods; Remote vs. In-Person Study Evaluation (RISE) Trials
Completed
·
S
State University of New York at Buffalo
·
Preclinical
·
NCT06822049
·
200 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
3 trial records for Combination nicotine replacement therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Combination nicotine replacement therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Combination nicotine replacement therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
State University of New York at Buffalo company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
S
State University of New York at Buffalo
Related News